ClinicalTrials.gg
Sign In

Drug

Anti-HER2 Bispecific Antibody TQB2930 clinical trials

studies test it
4
open now
3
in phase 3
1
first study started
2022

Keep track of what changes. Save the Anti-HER2 Bispecific Antibody TQB2930 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Combined with it in one product

TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
1
TQB2930 injection+TQB2102 for injection
1

Studies by the year they started

4 studies that test it; most in 2026 (2)

Studies that test Anti-HER2 Bispecific Antibody TQB2930, by start year
YearStudies
20221
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Colorectal Neoplasms
1
Neoplasms
1

Who runs them

Industry 4 · Other 0

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (4)

Often tested with

Tested in the same studies.

Bevacizumab (1) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (1)

Studies

Open first, then newest update. How each study uses Anti-HER2 Bispecific Antibody TQB2930 is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 1 — Anti-HER2 Bispecific Antibody TQB2930 is usual care beside what is tested